The President’s Cancer Panel highlighted the sharp increase in U.S. cancer drug prices in a 70-page report to President Trump, calling for more value-based pricing, more competition in the drug market and “meaningful communication” about treatment options.

The panel recommended the use of a widely accepted value framework as a key step toward value-based pricing, saying an ideal framework would “integrate information on clinical outcomes, toxicities, impact on quality of life, and costs.”

Such a framework would “inform negotiations between drug manufacturers and payers and… could guide development of value-based payment models,” said the three-member panel, including Barbara Rimer, dean of the Gillings School of Global Public Health at the University of North Carolina , Owen Witte, a professor at UCLA, and actor and cancer survivor Hill Harper.